Targeting Kras: Pros and Cons of In Vitro Tools Versus Mouse Models
Time: 3:30 pm
day: Day One
- Can genetic models discriminate between tumour initiating and tumour maintaining effects of KRAS?
- Can we improve the identification of biomarkers for better treatment options?
- Can genetic models be used to predict the toxicity of new KRAS-specific drugs?